Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Antiviral Res. 2017 Dec 15;150:112–122. doi: 10.1016/j.antiviral.2017.12.008

Figure 3. Combination of ER α-glucosidase inhibitor IHVR-19029 and T-705 synergistically inhibited YFV and EBOV infection in vitro.

Figure 3

Antiviral activities of indicated doses of 19029 and T-705, either alone or in combination in a checkerboard Matrix format, were determined. (A) 293TLR3IFNβ Luc cells were seeded in 96-well plate for overnight and infected with either YFV at MOI of 0.1 for 1 hr. The cells were then treated with indicated concentrations of compounds or their combinations for additional 48 hrs followed by quantification of luciferase activity (n=6). (B) Hela cells were seeded in 384-well plate and treated with indicated concentrations of compounds or their combination for 2 hr. The cells were then infected with EBOV (Zaire) at MOI of 2.5 for 48 hrs. Immunostaining assay was performed to quantify EBOV GP protein (n=4). Synergy analysis was performed using MacSyngergy II. The peak above the surface represents the degree of synergy with 95% confidence interval.